FDA APPROVES FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR HER2-POSITIVE GASTRIC ADENOCARCINOMAS
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in patients with HER2-positive locally advanced or metastatic […]
FDA APPROVES FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR HER2-POSITIVE GASTRIC ADENOCARCINOMAS Read More »
